Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
38.39 (1y: +31%)
Market Cap 59.99 B P/E(ttm) 11.90
Enterprise Value 57.53 B P/B 2.20
ABT- NYSE (USA)
Abbott Laboratories
  • Currently 3.5/5
Business Predictability Rank: 3.5-Star
Back Testing Results:
Average gain of all 3.5-Star stocks: 9.3% per year.
% of Stocks that are in still loss if held for 10yrs: 9%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$38.39
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.741
ABT's Cash to Debt is ranked lower than
67% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.36 vs. ABT: 0.741 )
ABT' s 10-Year Cash to Debt Range
Min: 0.1   Max: 0.74
Current: 0.74
0.1
0.74
Equity to Asset 0.035
ABT's Equity to Asset is ranked lower than
90% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.52 vs. ABT: 0.035 )
ABT' s 10-Year Equity to Asset Range
Min: -0.1   Max: 0.46
Current: 0.04
-0.1
0.46
Interest Coverage 15.8
ABT's Interest Coverage is ranked lower than
74% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10000.00 vs. ABT: 15.8 )
ABT' s 10-Year Interest Coverage Range
Min: 7   Max: 146
Current: 15.8
7
146
F-Score: 7
Z-Score: 3.83
M-Score: -3.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 20.30
ABT's Operating margin (%) is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.70 vs. ABT: 20.30 )
ABT' s 10-Year Operating margin (%) Range
Min: 9.1   Max: 24.7
Current: 20.3
9.1
24.7
Net-margin (%) 15
ABT's Net-margin (%) is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. ABT: 15 )
ABT' s 10-Year Net-margin (%) Range
Min: 7.6   Max: 20.3
Current: 15
7.6
20.3
ROE (%) 22.3
ABT's ROE (%) is ranked higher than
97% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. ABT: 22.3 )
ABT' s 10-Year ROE (%) Range
Min: 12.2   Max: 32.9
Current: 22.3
12.2
32.9
ROA (%) 8.9
ABT's ROA (%) is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. ABT: 8.9 )
ABT' s 10-Year ROA (%) Range
Min: 4.7   Max: 18.2
Current: 8.9
4.7
18.2
ROC (Joel Greenblatt) (%) 60.70
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.40 vs. ABT: 60.70 )
ABT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.8   Max: 60.7
Current: 60.7
19.8
60.7
Revenue Growth (%) 5.9
ABT's Revenue Growth (%) is ranked higher than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.20 vs. ABT: 5.9 )
ABT' s 10-Year Revenue Growth (%) Range
Min: 4   Max: 9.3
Current: 5.9
4
9.3
EBITDA Growth (%) 6.1
ABT's EBITDA Growth (%) is ranked higher than
87% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.35 vs. ABT: 6.1 )
ABT' s 10-Year EBITDA Growth (%) Range
Min: -5.4   Max: 23.1
Current: 6.1
-5.4
23.1
EPS Growth (%) 0.2
ABT's EPS Growth (%) is ranked higher than
71% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. ABT: 0.2 )
ABT' s 10-Year EPS Growth (%) Range
Min: -10.6   Max: 34.7
Current: 0.2
-10.6
34.7
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ABT Guru Trades in Q2 2012

Paul Tudor Jones 4,700 sh (New)
Manning & Napier Advisors, Inc 207,372 sh (+81.7%)
PRIMECAP Management 4,124,647 sh (+45.41%)
Jeremy Grantham 14,545,356 sh (+9.43%)
Jim Simons 205,100 sh (+4.16%)
Diamond Hill Capital 3,742,303 sh (+1.14%)
Meridian Funds 9,400 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Robert Bruce 234,800 sh (unchged)
Dodge & Cox 38,263 sh (unchged)
Westport Asset Management 67,500 sh (unchged)
Murray Stahl 37,392 sh (unchged)
Vanguard Health Care Fund 12,100,000 sh (unchged)
Jean-Marie Eveillard Sold Out
John Rogers Sold Out
John Burbank Sold Out
David Dreman Sold Out
Ronald Muhlenkamp 427,400 sh (-0.1%)
Jeff Auxier 81,840 sh (-0.24%)
John Buckingham 97,265 sh (-1.25%)
Bill Frels 215,380 sh (-1.3%)
Richard Snow 38,256 sh (-2.68%)
Tom Russo 355,156 sh (-3.9%)
Pioneer Investments 3,058,001 sh (-4.04%)
Scott Black 33,535 sh (-7.89%)
Mason Hawkins 9,628,470 sh (-9.22%)
Mario Gabelli 76,107 sh (-27.57%)
Joel Greenblatt 10,088 sh (-43.99%)
John Hussman 351,000 sh (-53.26%)
Richard Pzena 1,869,118 sh (-58.9%)
Ken Fisher 26,578 sh (-93.99%)
Steven Cohen 3,700 sh (-98.82%)
» More
Q3 2012

ABT Guru Trades in Q3 2012

George Soros 200,000 sh (New)
Donald Yacktman 3,000 sh (New)
Steven Cohen 620,343 sh (+16666%)
Ken Fisher 159,867 sh (+501.5%)
Joel Greenblatt 16,426 sh (+62.83%)
Jim Simons 321,100 sh (+56.56%)
John Hussman 501,000 sh (+42.74%)
Richard Pzena 2,218,879 sh (+18.71%)
Pioneer Investments 3,401,398 sh (+11.23%)
PRIMECAP Management 4,559,547 sh (+10.54%)
Manning & Napier Advisors, Inc 222,249 sh (+7.17%)
Vanguard Health Care Fund 12,100,000 sh (unchged)
Murray Stahl 37,392 sh (unchged)
Robert Bruce 234,800 sh (unchged)
Meridian Funds 9,400 sh (unchged)
Westport Asset Management 67,500 sh (unchged)
Richard Snow Sold Out
Bill Frels 215,022 sh (-0.17%)
Dodge & Cox 38,063 sh (-0.52%)
Jeremy Grantham 14,436,509 sh (-0.75%)
Jeff Auxier 80,540 sh (-1.59%)
Scott Black 32,685 sh (-2.53%)
Diamond Hill Capital 3,614,531 sh (-3.41%)
John Buckingham 91,691 sh (-5.73%)
Mason Hawkins 7,949,000 sh (-17.44%)
Ronald Muhlenkamp 326,270 sh (-23.66%)
Paul Tudor Jones 3,500 sh (-25.53%)
Mario Gabelli 54,209 sh (-28.77%)
Tom Russo 104,550 sh (-70.56%)
» More
Q4 2012

ABT Guru Trades in Q4 2012

Daniel Loeb 1,834,000 sh (New)
George Soros 588,500 sh (+194.25%)
Mason Hawkins 14,754,193 sh (+85.61%)
PRIMECAP Management 7,369,047 sh (+61.62%)
Jim Simons 515,100 sh (+60.42%)
Ken Fisher 238,339 sh (+49.09%)
Mario Gabelli 59,740 sh (+10.2%)
Bill Frels 221,069 sh (+2.81%)
Manning & Napier Advisors, Inc 222,877 sh (+0.28%)
Meridian Funds 9,400 sh (unchged)
Jeremy Grantham 14,592,726 sh (unchged)
Vanguard Health Care Fund 10,150,000 sh (unchged)
Westport Asset Management 90,000 sh (unchged)
Scott Black Sold Out
Donald Yacktman Sold Out
Ronald Muhlenkamp Sold Out
Jeff Auxier 80,440 sh (-0.12%)
Dodge & Cox 38,015 sh (-0.13%)
Robert Bruce 234,300 sh (-0.21%)
Diamond Hill Capital 3,449,507 sh (-4.57%)
Joel Greenblatt 15,623 sh (-4.89%)
Paul Tudor Jones 3,300 sh (-5.71%)
Murray Stahl 34,292 sh (-8.29%)
John Buckingham 83,553 sh (-8.88%)
Richard Pzena 1,949,798 sh (-12.13%)
Tom Russo 89,300 sh (-14.59%)
Vanguard Health Care Fund 10,150,000 sh (-16.12%)
John Hussman 401,750 sh (-19.81%)
Pioneer Investments 2,265,392 sh (-33.4%)
Steven Cohen 241,206 sh (-61.12%)
» More
Q1 2013

ABT Guru Trades in Q1 2013

Robert Olstein 129,000 sh (New)
Paul Tudor Jones 10,500 sh (+218.18%)
Richard Pzena 4,434,735 sh (+127.45%)
Westport Asset Management 180,000 sh (+100%)
George Soros 1,140,752 sh (+93.84%)
PRIMECAP Management 11,683,747 sh (+58.55%)
Mario Gabelli 84,215 sh (+40.97%)
Bill Frels 294,370 sh (+33.16%)
Murray Stahl 36,003 sh (+4.99%)
Manning & Napier Advisors, Inc 225,079 sh (+0.99%)
Jeff Auxier 80,490 sh (+0.06%)
Robert Bruce 234,300 sh (unchged)
John Hussman 401,750 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Meridian Funds Sold Out
Daniel Loeb Sold Out
Steven Cohen Sold Out
Dodge & Cox 37,865 sh (-0.39%)
Jeremy Grantham 14,485,435 sh (-0.74%)
Mason Hawkins 14,554,678 sh (-1.35%)
Tom Russo 87,700 sh (-1.79%)
John Buckingham 82,008 sh (-1.85%)
Pioneer Investments 2,220,980 sh (-1.96%)
Diamond Hill Capital 3,197,415 sh (-7.31%)
Vanguard Health Care Fund 9,347,700 sh (-7.9%)
Ken Fisher 11,528 sh (-95.16%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Daniel Loeb 2013-03-31 Sold Out 1.1%$31.34 - $35.32 $ 37.7212%0
George Soros 2013-03-31 Add 93.84%0.23%$31.34 - $35.32 $ 37.7212%1140752
PRIMECAP Management 2013-03-31 Add 58.55%0.23%$31.34 - $35.32 $ 37.7212%11683747
Joel Greenblatt 2013-03-31 Sold Out 0.06%$31.34 - $35.32 $ 37.7212%0
Meridian Funds 2013-03-31 Sold Out 0.02%$31.34 - $35.32 $ 37.7212%0
Mario Gabelli 2013-03-31 Add 40.97%0.01%$31.34 - $35.32 $ 37.7212%84215
Ronald Muhlenkamp 2012-12-31 Sold Out 4.7%$30.09 - $34.51 $ 37.7219%0
Mason Hawkins 2012-12-31 Add 85.61%1.43%$30.09 - $34.51 $ 37.7219%14754193
Daniel Loeb 2012-12-31 New Buy1.1%$30.09 - $34.51 $ 37.7219%1834000
Scott Black 2012-12-31 Sold Out 0.33%$30.09 - $34.51 $ 37.7219%0
George Soros 2012-12-31 Add 194.25%0.3%$30.09 - $34.51 $ 37.7219%588500
PRIMECAP Management 2012-12-31 Add 61.62%0.27%$30.09 - $34.51 $ 37.7219%7369047
Donald Yacktman 2012-12-31 Sold Out 0.0012%$30.09 - $34.51 $ 37.7219%0
Ronald Muhlenkamp 2012-09-30 Reduce -23.66%1.51%$63.95 - $69.84 $ 37.72-43%326270
John Hussman 2012-09-30 Add 42.74%0.25%$63.95 - $69.84 $ 37.72-43%501000
George Soros 2012-09-30 New Buy0.22%$63.95 - $69.84 $ 37.72-43%200000
Joel Greenblatt 2012-09-30 Add 62.83%0.03%$63.95 - $69.84 $ 37.72-43%16426
Mario Gabelli 2012-09-30 Reduce -28.77%0.01%$63.95 - $69.84 $ 37.72-43%54209
Donald Yacktman 2012-09-30 New Buy$63.95 - $69.84 $ 37.72-43%3000
John Hussman 2012-06-30 Reduce -53.26%0.47%$59.49 - $63.4 $ 37.72-39%351000
John Burbank 2012-06-30 Sold Out 0.21%$59.49 - $63.4 $ 37.72-39%0
PRIMECAP Management 2012-06-30 Add 45.41%0.14%$59.49 - $63.4 $ 37.72-39%4124647
Joel Greenblatt 2012-06-30 Reduce -43.99%0.04%$59.49 - $63.4 $ 37.72-39%10088
David Dreman 2012-06-30 Sold Out 0.01%$59.49 - $63.4 $ 37.72-39%0
Mario Gabelli 2012-06-30 Reduce -27.57%0.01%$59.49 - $63.4 $ 37.72-39%76107
Jean-Marie Eveillard 2012-06-30 Sold Out $59.49 - $63.4 $ 37.72-39%0
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Abbott Laboratories

Guru Stocks at 52-Week Highs
April 15, 2013
According to GuruFocus' list of 52-week highs, these Guru stocks have reached their 52-week highs. Read more...
Weekly 52 Week Highs: ABBV, ABT, YUM, AET
February 11, 2013
According to GuruFocus Insider Data, these are the largest insider buys during the past week: AbbVie Inc. (ABBV), Abbot Laboratories (ABT), Yum! Brands Inc. (YUM), and Aetna Inc. (AET). Read more...
Mason Hawkins' Southeastern Discusses Abbott Labs
May 23, 2012
Southeastern's Ross Glotzbach discusses the firm's investment in Abbott Labs. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 11.90
ABT's P/E(ttm) is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.76 vs. ABT: 11.90 )
ABT' s 10-Year P/E(ttm) Range
Min: 5.78   Max: 28.44
Current: 11.9
5.78
28.44
P/B 2.20
ABT's P/B is ranked higher than
68% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ABT: 2.20 )
ABT' s 10-Year P/B Range
Min: 1.39   Max: 4.55
Current: 2.2
1.39
4.55
P/S 1.50
ABT's P/S is ranked higher than
70% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. ABT: 1.50 )
ABT' s 10-Year P/S Range
Min: 0.96   Max: 2.76
Current: 1.5
0.96
2.76
PFCF 10.40
ABT's PFCF is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. ABT: 10.40 )
ABT' s 10-Year PFCF Range
Min: 4.38   Max: 23.61
Current: 10.4
4.38
23.61
EV-to-EBIT 8.4
ABT's EV-to-EBIT is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.70 vs. ABT: 8.4 )
ABT' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 29.7
Current: 8.4
6.7
29.7
PEG 1.5
ABT's PEG is ranked higher than
88% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. ABT: 1.5 )
ABT' s 10-Year PEG Range
Min: 0.35   Max: 36.85
Current: 1.5
0.35
36.85
Shiller P/E 11.8
ABT's Shiller P/E is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.12 vs. ABT: 11.8 )
ABT' s 10-Year Shiller P/E Range
Min: 8.21   Max: 15.05
Current: 11.8
8.21
15.05

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 3.50
ABT's Dividend Yield is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. ABT: 3.50 )
ABT' s 10-Year Dividend Yield Range
Min: 3.03   Max: 7.9
Current: 3.5
3.03
7.9
Dividend Payout 0.5046
ABT's Dividend Payout is ranked higher than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.86 vs. ABT: 0.5046 )
ABT' s 10-Year Dividend Payout Range
Min: 0.42   Max: 1.04
Current: 0.5
0.42
1.04
Dividend growth (3y) 6.5
ABT's Dividend growth (3y) is ranked higher than
94% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.95 vs. ABT: 6.5 )
ABT' s 10-Year Dividend growth (3y) Range
Min: 4.4   Max: 8.5
Current: 6.5
4.4
8.5
Yield on cost (5-Year) 5.35
ABT's Yield on cost (5-Year) is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. ABT: 5.35 )
ABT' s 10-Year Yield on cost (5-Year) Range
Min: 4.77   Max: 12.44
Current: 5.35
4.77
12.44
Share Buyback Rate -0.7
ABT's Share Buyback Rate is ranked higher than
85% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.00 vs. ABT: -0.7 )
ABT' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -0.7
Current: -0.7

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 7.8
ABT's Price/Net Current Asset Value is ranked higher than
64% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. ABT: 7.8 )
ABT' s 10-Year Price/Net Current Asset Value Range
Min: 5.1   Max: 13.5
Current: 7.8
5.1
13.5
Price/Tangible Book 25.1
ABT's Price/Tangible Book is ranked higher than
98% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. ABT: 25.1 )
ABT' s 10-Year Price/Tangible Book Range
Min: 4.8   Max: 22.2
Current: 25.1
4.8
22.2
Price/DCF (Projected) 0.7
ABT's Price/DCF (Projected) is ranked higher than
69% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABT: 0.7 )
ABT' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 0.9
Current: 0.7
0.4
0.9
Price/Median PS Value 1.1
ABT's Price/Median PS Value is ranked higher than
84% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.70 vs. ABT: 1.1 )
ABT' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.6
Current: 1.1
0.7
1.6
Price/Peter Lynch Fair Value 1.7
ABT's Price/Peter Lynch Fair Value is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. ABT: 1.7 )
ABT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 1.6
Current: 1.7
0.4
1.6
Price/Graham Number 3.4
ABT's Price/Graham Number is ranked higher than
83% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. ABT: 3.4 )
ABT' s 10-Year Price/Graham Number Range
Min: 1.6   Max: 5
Current: 3.4
1.6
5
Earnings Yield (Greenblatt) 11.90
ABT's Earnings Yield (Greenblatt) is ranked higher than
90% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. ABT: 11.90 )
ABT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 15
Current: 11.9
3.4
15
Forward Rate of Return (Yacktman) 16.34
ABT's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.82 vs. ABT: 16.34 )
ABT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.5   Max: 35.1
Current: 16.34
6.5
35.1

Business Description

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's main business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products. Abbott has five reportable revenue segments: Proprietary Pharmaceutical Products, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Proprietary Pharmaceutical Products includes Humira, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease; TriCor, Trilipix, Simcor, and Niaspan, for the treatment of dyslipidemia; Kaletra, also marketed as Aluvia, and Norvir, protease inhibitors for the treatment of HIV infection. Established Pharmaceutical Products includes Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Influvac, an influenza vaccine available during flu season; Serc, for the treatment of Ménière's disease and vestibular vertigo; Brufen, for the treatment of pain, fever and inflammation. Diagnostic Products include immunoassay and clinical chemistry systems, including ARCHITECT, AxSYM, and ABBOTT PRISM; the m2000, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents including HIV, HBV, HCV, HPV, and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit; the UroVysion bladder cancer recurrence kit; and the Vysis ALK Break Apart FISH Probe Kit, the only FDA-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI. Nutritional Products include various forms of prepared infant formula and follow-on formula, including SimilacAdvance, Similac Advance with EarlyShield, Similac, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Isomil Advance, Isomil, Alimentum, Gain, and Grow; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Muscle Health, Ensure (with Nutrivigor), Glucerna, Glucerna Hunger Smart, PediaSurePro SurePro-SurePressureProcureProsier">ProSure, PediaSure, PediaSure Sidekicks, EleCare, Juven, Abound, and Pedialyte; nutritional products used in enteral feeding in health care institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, and Nepro; and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge. Vascular Products include: Xience Prime, Xience nano, and Xience V, drug-eluting stent systems developed on the Multi-Link Vision platform; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager, balloon
Company Website
SEC Reports
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS
Traded in other countries:ABT.UK, ABT.Switzerland, ABL.Germany
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Guru Stocks at 52-Week Highs Apr 15 2013 
14 Cheapest Dividend-Paying Large Caps As of March 2013 Mar 23 2013 
Weekly 52 Week Highs: ABBV, ABT, YUM, AET Feb 11 2013 
Should dividend investors hold on to Abbott and Abbvie following the split? Feb 01 2013 
Reconsidering Abbott Labs (ABT) And AbbVie (ABBV) Jan 18 2013 
Why Cooperman and Price Are Betting on Boston Scientific’s Turnaround Dec 31 2012 
Abbott Laboratories (ABT) Dividend Stock Analysis Dec 27 2012 
9 High-Yielding Mega-Cap Stocks Dec 26 2012 
Abbott Laboratories: Quality Dividend Aristocrat for Long Term Dividends Dec 21 2012 
Dividend Stocks I Purchased Over the Past Two Months Dec 19 2012 

More From Our Partners
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent May 21 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial